ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,957.64
0.68%
US Tech 100
20,247.60
0.60%
다우존스 지수
43,918.39
1.17%
Bitcoin
98,545.99
4.44%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ

  6. Esperion Therapeutics Inc (ESPR) 시세

Esperion Therapeutics Inc

Esperion Therapeutics Inc (ESPR)

NASDAQ
2.48
0.065
( 2.69% )
업데이트: 05:17:18
15분 지연

실시간 토론 및 거래 아이디어: 강력한 플랫폼으로 자신있게 거래하세요.

프리미엄

주요 통계 및 세부정보

가격
2.48
매수가
2.47
매도가
2.48
거래량
2,543,961
2.35 일간 변동폭 2.51
1.15 52주 범위 3.40
market_cap
488.647M
전일 종가
2.415
개장가
2.39
최근 거래 시간
100
@
2.48
마지막 거래 시간
05:19:39
재정 규모
US$ 6,233,742
VWAP
2.4504
평균 볼륨(3m)
3,826,987
발행 주식
197,035,171
배당수익률
-
주가수익률
-2.33
주당순이익(EPS)
-1.06
매출
116.33M
순이익
-209.25M

Esperion Therapeutics Inc 정보

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializi... Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. 더 보기

섹터
Pharmaceutical Preparations
산업
Pharmaceutical Preparations
웹사이트
www.esperion.com
본부
Wilmington, Delaware, USA
설립됨
-
Esperion Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the 나스닥 with ticker ESPR. The last closing price for Esperion Therapeutics was US$2.42. Over the last year, Esperion Therapeutics shares have traded in a share price range of US$ 1.15 to US$ 3.40.

Esperion Therapeutics currently has 197,035,171 shares in issue. The market capitalisation of Esperion Therapeutics is US$475.84 million. Esperion Therapeutics has a price to earnings ratio (PE ratio) of -2.33.

ESPR 최신 뉴스

추가 뉴스

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference

ANN ARBOR, Mich., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Piper Sandler 36th Annual Healthcare...

8 시간 전
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

23 시간 전
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

20 11월 2024
Edgar (US Regulatory)

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

– An Exploratory Analysis Reports Patients with PAD Who Took Bempedoic Acid Were 36% Less Likely to Experience a Major Adverse Limb Event Compared to Placebo – ANN ARBOR, Mich., Nov. 18, 2024...

19 11월 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

14 11월 2024
Edgar (US Regulatory)

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANN ARBOR, Mich., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 7, 2024, the Company granted four new employees 12,900 restricted stock units (RSUs...

09 11월 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

08 11월 2024
Edgar (US Regulatory)

Form 8-K - Current report

07 11월 2024
Edgar (US Regulatory)

Esperion Reports Third Quarter 2024 Financial Results and Provides a Business Update

– Total Revenue Increased 52% Year-over-Year to $51.6 Million with U.S. Net Product Revenue of $31.1 Million, Representing 53% Growth – – Total Retail Prescription Equivalents Increased 12% and...

07 11월 2024
GlobeNewswire Inc.

Esperion to Participate in Upcoming Jefferies London Healthcare Conference

ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on...

04 11월 2024
GlobeNewswire Inc.
기간변동변동 %시가고가저가평균 일일 거래량VWAP
10.2611.71171171172.222.512.0253728342.23135235CS
40.4220.38834951462.062.61.8751807402.22585875CS
120.7946.74556213021.692.61.5838269872.02677398CS
26002.483.121.5850319692.23037102CS
521.25101.626016261.233.41.1558931562.29142925CS
156-5-66.84491978617.4810.020.735331542.84888725CS
260-42.39-94.47292177444.8779.9890.724027386.33978947CS

이동자

모두 보기
  • 가장 활성
  • % 상승자
  • % 패자
기호가격볼륨
WORXSCWorx Corporation
US$ 2.135
(117.86%)
134.47M
CRNCCerence Inc
US$ 5.8199
(106.38%)
72.76M
ARQQArqit Quantum Inc
US$ 10.54
(43.60%)
762.64k
SPAISafe Pro Group Inc
US$ 4.55
(42.19%)
42M
PROCProcaps Group SA
US$ 0.785
(37.36%)
1.23M
SKKSKK Holdings Limited
US$ 0.8208
(-82.00%)
28.75M
WCTWellchange Holdings Company Limited
US$ 1.23
(-62.95%)
1.97M
TMTCTMT Acquisition Corporation
US$ 2.40
(-62.73%)
371.32k
TMTCUTMT Acquisition Corporation
US$ 2.99
(-55.24%)
11.76k
GLXGGalaxy Payroll Group Ltd
US$ 1.79
(-54.22%)
2.24M
CDTConduit Pharmaceuticals Inc
US$ 0.1054
(14.19%)
555.92M
NVDANVIDIA Corporation
US$ 148.3124
(1.66%)
330.41M
ELABElevai Labs Inc
US$ 0.02015
(-5.84%)
222.67M
AKTSAkoustis Technologies Inc
US$ 0.103
(18.25%)
200.72M
MARAMARA Holdings Inc
US$ 24.56
(8.53%)
142.11M

ESPR Discussion

게시물 보기
Gregg4 Gregg4 1 일 전
All looks good
👍️0
FACT-MASTER FACT-MASTER 1 일 전
Accumulation in progress, imo.

Trading here has taken a turn to the positive, imo, ask walls methodically being taken out.

Hope i don't get side smacked for stating that analysis.
👍 1
FACT-MASTER FACT-MASTER 2 일 전
Sounds like today's Jefferies conference was a bit more optimistic.

I'm not a member on st but often read that board, many good posters there.

https://www.thelion.com/bin/aio_msg.cgi?cmd=search&symbol=espr
👍️0
nsomniyak nsomniyak 2 일 전
Agreed.
👍️0
FACT-MASTER FACT-MASTER 2 일 전
Nice move today with good volume!

Looks like bidding was strong today, that's weird,,,, for ESPR.
👍 1
FACT-MASTER FACT-MASTER 2 일 전
Thanks for that information, however that being the case, management failed to use the opportunity to bridge some trust with the investing community by re-confirming a commitment to building shareholder value / working in the best interests of shareholders / pledging to cease share based executive compensation until the company reaches profitability / outline a plan to profitability / detail expense restraint / and outlining a plan to profitability.

I concur that 2024 has been a pivotal year of accomplishment, however the marketplace appears to be skeptical of ESPR mgmt. The current share price and market cap suggests a loss of confidence in ESPR mgmt., imo.
👍️0
Gregg4 Gregg4 2 일 전
Yup someone is buying trying to keep under wraps
👍️0
nsomniyak nsomniyak 3 일 전
The interview was sponsored by Esperion. That means the interviewer was given a predetermined script written by Esperion, he was not free to ask "top of mind" questions from a shareholder's point of view.

There were no questions about stock performance because Esperion did not want to answer any such questions.
👍️0
FACT-MASTER FACT-MASTER 3 일 전
ESPR: On deck for November 19/24

Jefferies London Healthcare Conference

https://www.esperion.com/events/event-details/jefferies-london-healthcare-conference-3

Will it be a re-hash of the poster presentations this past weekend or does Sheldon have something new to lift the spirits of long term shareholders, we will see tomorrow.

Interesting late day trading the last couple of sessions.
👍 1
Gregg4 Gregg4 3 일 전
I agree never hard questions 
👍️0
FACT-MASTER FACT-MASTER 3 일 전
https://www.fiercehealthcare.com/sponsored/2024-pivotal-year-fight-against-cardiovascular-disease

I'm always surprised that the interviewer never asks the respondant about the share price performance. If it been such a pivotal year of accomplishments, why has the stock lost approx. 50% since January 1/24?? Sheldon, can you comment on that and please expand on where you think the market cap should be and/or what exactly is the problem with ESPR stock performance?
👍 1
FACT-MASTER FACT-MASTER 3 일 전
ESPR: Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024

https://finance.yahoo.com/news/esperion-highlights-exploratory-data-clear-153000058.html


Sellers just can't sell enough, level II ask keeps loading. Level II = hopeless for ESPR, imo.
👍 1
FACT-MASTER FACT-MASTER 5 일 전
Esperion Corporate presentation November 2024

https://www.esperion.com/static-files/c900cfb6-ec24-45cf-81a5-ee14d1836a53

Looks like a NDA in Canada during November (slide 11) - no big deal, imo.
👍 1
FACT-MASTER FACT-MASTER 1 주 전
The Vanguard Group reported 10,816,762 shares held as of June 30/24.

https://www.nasdaq.com/market-activity/stocks/espr/institutional-holdings

The Vanguard Group reported 13,043,077 shares held as of September 30/24

https://archive.fast-edgar.com/20241104/AB22M222Z222VJD222222ZO2LQ2ST322B262/UnitedStates_13G__EsperionTh.txt

Increase of 2,226,315 shares in the 3rd quarter
👍 1
Gregg4 Gregg4 1 주 전
Hope so been long almost 4 years
👍️0
FACT-MASTER FACT-MASTER 1 주 전
It seems something big is in the works.

Haven't seen Level II act the way it did today, ask in the low 2.50-2.53 were getting repeatedly annihilated.

Could be a major partnering, or a buyout in the works, imo.
👍️0
Gregg4 Gregg4 1 주 전
Yes one trade almost a million shares 
👍️0
FACT-MASTER FACT-MASTER 1 주 전
AH volume on fire!

https://www.nasdaq.com/market-activity/stocks/espr/after-hours
👍️0
Gregg4 Gregg4 1 주 전
Yup
👍️0
FACT-MASTER FACT-MASTER 1 주 전
Strong to the close.

Looking good!, imo.
👍 1
FACT-MASTER FACT-MASTER 2 주 전
WOW! nice move north!

Level II bid looking pretty strong.

Pleasantly surprised here this morning!
👍 1
FACT-MASTER FACT-MASTER 2 주 전
Nascar promotional collaboration 2024 has failed, imo

https://www.esperion.com/news-releases/news-release-details/rfk-esperion-therapeutics-announce-2024-promotional-schedule

It's time for ESPR mgmt. to get serious and employ competent, dedicated sales reps who know how to get the job done!

https://www.youtube.com/shorts/zlkURHOXkKs
👍 1
FACT-MASTER FACT-MASTER 2 주 전
ESPR: Form 10-Q

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024046307/espr-20240930.htm
👍️0
FACT-MASTER FACT-MASTER 2 주 전
ESPR: No funds available to redeem convert.notes, imo.

Cash and cash equivalents $ 144,717,000

and losing 30$ million per quarter - does not look good, imo
👍️0
FACT-MASTER FACT-MASTER 2 주 전
ESPR: For what??? Losing money?? ( in bold below)

2024 Financial Outlook

The Company reiterates its full year 2024 operating expense guidance, which is expected to be approximately $225 million to $245 million, including $20 million in non-cash expenses related to stock compensation.

and here under SG&A

The increase is primarily related to the ramp up of our sales force associated with our commercial launch in addition to bonus payments and promotional costs.

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

ESPR mgmt. spending appears to be out of control. imo.

Only positive today is that ESPR is not sub$2, imo.
👍️0
FACT-MASTER FACT-MASTER 2 주 전
ESPR: Official earnings SEC filing

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001434868/000162828024045984/espr-20241107.htm

Problem areas, imo:

Selling, general and administrative 39,975,000
Interest expense (15,082,000)

Whatever they are spending money on in the "Selling, general and administrative" like NasCar and sales reps - it's not working.

Overall prognosis is poor, and financials are weak.

No news on the converts in the near term will mean no profitability anytime soon, imo.
👍 1
FACT-MASTER FACT-MASTER 2 주 전
ESPR:
👍️0
FACT-MASTER FACT-MASTER 2 주 전
$2.25 rejected.

Perpetual wall on the ask at $2.25.

What are we anticipating for tomorrow's earnings call?

It seems positive imo, that the earnings release is prior to the open, as opposed to releasing the earnings after the close.
👍 1
FACT-MASTER FACT-MASTER 4 주 전
scriptstrend on ST shares some good points.

https://stocktwits.com/scriptstrend2024/message/590178774

ESPR mgmt. needs to pay attention:

https://www.youtube.com/shorts/aZctsTD1iJY
👍 1
Gregg4 Gregg4 4 주 전
Guess we will see 11/7
👍️0
FACT-MASTER FACT-MASTER 4 주 전
I'm not expecting anything spectacular from the 3rd quarter results.

ESPR management team has failed long term investors by squandering shareholder value.
From what i have seen here, their expenditures are not translating into sales.

Great clinical trial results / great product / stock price barely holding a measly $2 dollars says ESPR management has failed - big time, imo.
👍️0
Gregg4 Gregg4 4 주 전
Just dreaming probably nothing but I'm hoping start of a long march upward 
👍️0
FACT-MASTER FACT-MASTER 4 주 전
Is what?
👍️0
Gregg4 Gregg4 4 주 전
This is it
👍️0
FACT-MASTER FACT-MASTER 4 주 전
Esperion to Report Third Quarter 2024 Financial Results on November 7

https://finance.yahoo.com/news/esperion-report-third-quarter-2024-120000845.html
👍️0
FACT-MASTER FACT-MASTER 1 월 전
https://finance.yahoo.com/news/millennium-management-llcs-strategic-reduction-230255195.html

As i mentioned previously, there could be something that is repulsive regarding ESPR mgmt.
A fund just doesn't dump that many shares at a bargain price for no reason. Something made then lose interest big time, and the only thing i can think of is ESPR mgmt.

Did this fund take a huge loss upon selling that huge portion of ESPR stock?

Not good, imo.
👍️0
Gregg4 Gregg4 2 월 전
I agree
👍️0
FACT-MASTER FACT-MASTER 2 월 전
I think it would be logical, imo, if ESPR was going to make a move to redeem the convertible notes, to do so on the issue/maturity anniversary date - Nov.15.

If they were to redeem them this year that would be one year prior to the final maturity of November 15/25.

That makes sense, imo, so if they are going to move on the convertible notes this year, we should be hearing about details between now and say November 5/10ish.
👍️0
glenn1919 glenn1919 2 월 전
ESPR.........................https://stockcharts.com/h-sc/ui?s=ESPR&p=W&b=5&g=0&id=p86431144783
👍️0
Gregg4 Gregg4 2 월 전
Love it
👍️0
FACT-MASTER FACT-MASTER 2 월 전
Another great day here at ESPR!

AH $2.18
👍️0
Gregg4 Gregg4 2 월 전
Yes thanks still need to make up ground
👍️0
FACT-MASTER FACT-MASTER 2 월 전
Comprende amigo.

I think your on the right track now, i do the same, only buy stock, stay out of options / etf's etc.

Your off to a great start today!
👍️0
Gregg4 Gregg4 2 월 전
No I lost massive cash in options past few months August and September I sold all my shares and went to options last fall when we hit .70 did very we’ll be played the game too long got burned three years makes u impatient so I started over with stock only
👍️0
FACT-MASTER FACT-MASTER 2 월 전
Congrats on that! looks like you picked a good day to get in.

Did you previously sell out, and now just bought back in?

I thought you were a dedicated bagholder like the rest of us, (lol)
👍️0
Gregg4 Gregg4 2 월 전
Back in all stock 57,620 $1.65
👍️0
Gregg4 Gregg4 2 월 전
I get it too if company so great why is it at $1.65 still
👍️0
FACT-MASTER FACT-MASTER 2 월 전
I must say, i like the conviction you have about ESPR, along with the other guys on st - i see some of those guys are still buying too.

If i didn't have any shares, i would be buying at this level too, however i'v lost some confidence in mgmt and just in a holding pattern for now.

I'm hoping for news on redemption of the convertible notes. That is the remaining obstacle, imo, before this story elevates to a higher level.

All the best with your purchases tomorrow.
👍️0
Gregg4 Gregg4 2 월 전
I’m buying this tomorrow both fists 60k shares
👍️0
FACT-MASTER FACT-MASTER 2 월 전
RED...., again - what else is new with ESPR
👍️0

최근 히스토리

NASDAQ
ESPR
Esperion Therapeutics
BIT
WAEDES
Aedes
BOV
WLMM4
WLM PN
AQSE
MAX
MaxRets Ventures
USOTC
AFRAF
Air France KLM (PK)
USOTC
PSYGF
Psyence (PK)
USOTC
PGAI
P G I (CE)
NYSE
ATH-A
Athene
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유